Claritev Corporation is a technology, data, and insights company focused on improving transparency, affordability, and quality within the U.S. healthcare system. Founded in 1980, the company provides objective, market-based insights to support complex healthcare decisions by applying data, analytics, and artificial intelligence. Its business is organized into four solution categories: Claims Intelligence Solutions, which include algorithms to detect anomalous pricing and negotiate fair market value reimbursements, along with Vistara solutions for reference-based pricing; Network Solutions, which involve contracted provider discounts and network management; Payment and Revenue Integrity Solutions, which identify improper charges and restore underpaid premiums; and Data and Analytics Solutions, which offer descriptive, predictive, and prescriptive analytics for benefit plan design and clinical outcomes. Claritev serves a client base of payers, including administrative services only platforms and third-party administrators, as well as employers, plan sponsors, providers, and government agencies. The company operates a proprietary data and technology platform that integrates with client environments to process claims prior to payment. Through internal development and acquisitions, Claritev has expanded its addressable markets to include payer risk analytics and network transparency services.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Health Information Services Homepage claritev.com
Sector Healthcare IR page claritev.com
Tags
healthcare data analytics, claims intelligence, payment integrity, network management, utilization management, reference-based pricing, revenue integrity, benefit plan design, third-party administration, healthcare cost management, Vistara, Claritev Cares
Press page claritev.com/who-we-are/newsroom

Metrics

Valuation  
Market cap $ 461.901M
Market cap (USD) $ 461.901M
P/E -1.65
PEG —
P/BV -1.33
P/S 0.45
P/OCF 3.52
P/FCF -16.61
Dividend yield —
Turnover / mcap —
Returns  
ROE 163.5%
ROI -6.4%
ROIC 0.48%
Profit margin -29.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 12
Quality score -37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 965.413M 930.624M 961.524M 1.08B 1.118B 937.763M 982.901M
Net profit -284.282M -1.646B -91.697M -572.912M 102.08M -520.564M 9.71M
Free cash flow -12.277M -10.507M 62.868M 282.629M 320.097M 306.561M 217.899M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 42.75 14.78 1.44 1.15 4.43 7.99 —
Price performance 12m 1.89 9.26 0.25 -0.74 -0.45 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 77.1M 63.2M 99.9M 78.9M 76.6M 89.8M 128M
↳ YoY growth -18.0% +58.1% -21.0% -3.0% +17.2% +42.2%
↳ 5y CAGR +3.1% +15.1%
Borrowings, current (USD) — — — 0.00 13.3M 13.3M 13.3M 13.3M 14.7M
Borrowings, non-current (USD) — — 5.4B 4.58B 4.88B 4.74B 4.53B 4.51B 4.56B
Lease liabilities (USD) — — 32.7M 34M 33.7M 27.3M 21.9M 18.3M 21.1M
Cash and deposits (USD) 21.4M 5.01M 21.8M 127M 185M 334M 71.5M 16.8M 16.8M
Intangible assets (USD) — — 3.89B 3.58B 3.29B 2.94B 2.63B 2.23B 1.88B
Right-of-use assets (USD) — — 30M 31.3M 30.1M 24.2M 19.7M 16.1M 14M
Net debt (borrowings + leases - cash) (USD) — — 5.41B 4.49B 4.74B 4.45B 4.5B 4.52B 4.58B
Cash flow detail
Operating cash flow (USD) — 292M 284M 377M 405M 372M 172M 108M 117M
Purchases of property, plant and equipment (USD) — -63.6M -66.4M -70.8M -84.6M -89.7M -109M -118M -130M
Change in receivables (cash effect) (USD) — 3.02M 5.28M 14.8M -33.8M 21M 4.4M -13.2M -26.6M
Change in payables (cash effect) (USD) — -40.4M 20.8M 29.1M 7.71M 34.3M -13.1M 42.2M -25.9M
Share buybacks (cash effect) (USD) — 0.00 0.00 -101M -100M 0.00 -15.2M -10.4M 0.00
Interest paid (cash effect) (USD) — -374M -364M -312M -231M -290M -323M -315M -283M
Income taxes paid (cash effect) (USD) — -117M -115M -3.92M -132M -124M -100M -80.1M -44.5M
Share-based compensation (USD) — 4.72M -14.9M 406M 18M 16.7M 18M 26.6M 27.8M
Operating cash flow before change in receivables (USD) — 289M 279M 363M 439M 351M 167M 121M 144M
Free cash flow (OCF - PPE - intangibles) (USD) — 229M 218M 307M 320M 283M 62.9M -10.5M -12.3M
Income detail
Total comprehensive income (USD) — 36.2M 9.71M -521M 102M -573M -103M -1.64B -283M
Comprehensive income to owners (USD) — 36.2M 9.71M -521M 102M -573M -103M -1.64B -283M
Provision for credit losses (USD) — 0.00 0.00 58,000 0.00 0.00 33,000 0.00 22,000
Credit cost ratio (credit losses / average receivables) (%) — — — 0.1% 0.0% 0.0% 0.0% 0.0% 0.0%
Reported Mar 16, 2021 Mar 16, 2021 Mar 16, 2021 Feb 25, 2022 Feb 25, 2022 Mar 1, 2023 Feb 29, 2024 Feb 26, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

–Q3 2026 Revenues of $268.3 million grew 9.1% compared to Q3 2025

–Net Loss of $61.8 million

–Adjusted EBITDA of $162.0 million increased 4.4% compared to Q3 2025

(Adjusted EBITDA Margin of 60.4% versus 63.1% in Q3 2025)

McLean, VA — November 9, 2026 — Claritev Corporation ("Claritev" or the "Company") (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the third quarter ended September 30, 2026.

"This quarter captured what we mean by delivering on our promises," said Travis Dalton, Chairman, CEO and President of Claritev. "Our teams executed with focus, our clients responded to the value we are bringing them, and results came in ahead of our expectations. What stands out most to me is the breadth of what our team is delivering: growth across our solutions and our verticals, and an innovation engine, including dozens of AI agents already at work inside our workflows, that is raising the bar for how we serve our clients."

Mr. Dalton added, "Our recent Client Conference made that momentum tangible.

Claritev logo in white with a blue and green circular icon on a dark navy branded background

MCLEAN, VA – November 5, 2026 – Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that members of its management team will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Wednesday, November 11, 2026, in New York, including a presentation at 3:30 p.m. ET.

To listen to the webcast, please visit https://investors.claritev.com . For one-on-one meetings, please contact a representative at the host firms.

About Claritev 

Claritev is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality across the U.S. healthcare system. Led by deeply experienced associates, data scientists, and innovators, Claritev provides technology-enabled solutions fueled by decades of claims expertise. The company leverages advanced analytics and AI to power a robust enterprise platform that delivers clear, actionable insights to support affordability, price transparency, and optimized network and benefits design. By supporting key stakeholders — including payers, employers, patients, providers, and third parties — Claritev is dedicated to making healthcare more accessible and affordable for all.

Claritev serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com .

Contacts

INVESTOR RELATIONS CONTACT

Todd Friedman
Head of Investor Relations & Strategic Communications 
Claritev
[email protected]  

MEDIA RELATIONS CONTACT

Jen O’Connor 
Vice President, Brand Marketing
Claritev[email protected]  

Recent news

  • Claritev

    Claritev Corporation Announces Participation in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

    Nov 5, 2026 | Newsroom

    Read More

  • Claritev

    Claritev Introduces Transparency-Based Pricing, Turning Complex Public Market Data into Actionable Reimbursement Intelligence

    Oct 29, 2026 | Newsroom

    Read More

  • Claritev

    Claritev Appoints Jennifer Main to its Board of Directors

    Oct 15, 2026 | Newsroom

    Read More

All News

Claritev

Fortune Best Workplaces in Health Care


© 2026 Claritev Corporation. All rights reserved.

Notifications

New AI-enabled innovation translates complex government-required public transparency data into a flexible, market-informed, and explainable methodology for evaluating reimbursement strategies.

MCLEAN, VA — October 29, 2026 — Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company, today announced the launch of Transparency-Based Pricing , a new market-informed reimbursement intelligence solution designed to give payers and third-party administrators (TPAs) greater flexibility and confidence as they manage healthcare costs and reimbursement strategies. The solution translates government-required public transparency data into market inputs and supporting rationale that clients can use within their own individualized reimbursement approaches.

Healthcare costs remain one of the most consequential pressures facing payers, employers, and the people they serve. Organizations need reimbursement approaches that can accommodate different claims, service categories, geographies, plan designs, and client objectives, while providing reimbursement rationales they can understand, explain, and support.

Announced at Claritev’s annual Client Conference, Transparency-Based Pricing gives clients an additional market-informed methodology to evaluate alongside their existing reimbursement strategies. It is designed to make government-required public transparency data accessible and operational for each client in their day-to-day reimbursement decisions, rather than simply making more data available.

Federal transparency requirements have made substantial volumes of in-network negotiated-rates and out-of-network reimbursement data publicly available, creating a powerful new source of market information, but one that is difficult for most organizations to use effectively or at scale. Claritev is putting that government-required public transparency data to practical use, applying responsible, AI-enabled processes to ingest, clean, normalize, and standardize more than 1.7 trillion machine-readable file records. The Company then applies more than four decades of healthcare expertise to identify relevant market inputs, such as publicly available rates for comparable services, providers, and geographies, and generate reimbursement reference points from that public data that each client can evaluate for their individual claims.

Transparency-Based Pricing does more than put transparency data or rate benchmarks at a user’s fingertips. It provides source-traceable public market inputs, claim-level reimbursement reference points, and supporting rationales that can be applied through established claims workflows. Each client independently evaluates that information and determines the reimbursement amount for each claim under their own policies and business rules.

“Payers and TPAs are under real pressure to make reimbursement decisions that are consistent, well-supported, and workable across a wide range of client needs. But having access to vast troves of public pricing data is not the same as making sense of it,” said Sean Crandell, Senior Vice President and General Manager, Claims Intelligence, at Claritev. “Transparency-Based Pricing gives teams a clearer, more practical view of the market and a source-traceable reference point they can evaluate under their own reimbursement policies, without having to build and maintain an enormous data infrastructure themselves.”

Transparency-Based Pricing expands, rather than replaces, the reimbursement options available to Claritev clients. Each client can configure it alongside established approaches, including negotiated rates, Medicare-based methodologies, and other reference points, to support a particular claim, service category, geography, client strategy, or business objective. Claritev expects to make the methodology available across multiple cost-containment applications over time, expanding the ways employers can use market-informed reimbursement intelligence within their established operations.

Key capabilities include:

  • Putting transparency data to practical use: Converts complex, government-required public transparency data into standardized market inputs and source-traceable reimbursement reference points that clients can evaluate under their own reimbursement policies.
  • Supporting more informed reimbursement strategies: Gives payers and TPAs an additional market-informed reference point to evaluate as they manage reimbursement variation, medical cost trends, and varied plan requirements.
  • Providing explainable, supportable rationale: Delivers source-traceable public market inputs, repeatable outputs, and clear reimbursement rationale to support internal review and communications with clients and providers.
  • Bringing innovation into existing workflows: Makes sophisticated public data standardization and reimbursement intelligence available through established claims workflows, without requiring organizations to build and maintain their own transparency-data infrastructure.

Transparency-Based Pricing is part of Claritev’s broader Claims Intelligence portfolio , which helps clients manage healthcare costs and navigate the complexity of reimbursement through technology, data, and market expertise. The solution reflects Claritev’s approach to responsible AI: applying advanced technology to practical healthcare challenges while keeping explainability, traceability, human expertise, and individual client decision-making at the center.

About Claritev 

Claritev is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality across the U.S. healthcare system. Led by deeply experienced associates, data scientists, and innovators, Claritev provides technology-enabled solutions fueled by decades of claims expertise. The company leverages advanced analytics and AI to power a robust enterprise platform that delivers clear, actionable insights to support affordability, price transparency, and optimized network and benefits design. By supporting key stakeholders — including payers, employers, patients, providers, and third parties — Claritev is dedicated to making healthcare more accessible and affordable for all.

Claritev serves more than 750 healthcare payers, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com .

Contacts

MEDIA RELATIONS

Jen O’Connor 
Vice President, Brand Marketing 
Claritev
[email protected]  

INVESTOR RELATIONS

Todd Friedman 
Head of Investor Relations and Strategic Communication
Claritev
[email protected]  

SOURCE: Claritev Corporation 

Recent news

  • Claritev

    Claritev Introduces Transparency-Based Pricing, Turning Complex Public Market Data into Actionable Reimbursement Intelligence

    Oct 29, 2026 | Newsroom

    Read More

  • Claritev

    Claritev Appoints Jennifer Main to its Board of Directors

    Oct 15, 2026 | Newsroom

    Read More

  • Claritev

    Claritev Corporation Announces Third Quarter 2026 Earnings Conference Call

    Oct 14, 2026 | Newsroom

    Read More

All News

Claritev

Fortune Best Workplaces in Health Care


© 2026 Claritev Corporation. All rights reserved.

Notifications

Prompts

Claritev Corporation (ticker CTEV), listed in United States.

Company History

Date Change Detail
Feb 19, 2025 Renamed MULTIPLAN CORP → CLARITEV CORP
Aug 28, 2020 Renamed CHURCHILL CAPITAL CORP III → MULTIPLAN CORP
Jan 29, 2020 Renamed Butler Acquisition Corp → CHURCHILL CAPITAL CORP III
— Former tickers MPLN

ETFs Holding Claritev Corporation

ETF Weight in ETF Shares Market value As of
DFAU 0.00% 524 $ 14.096K Nov 12, 2026
DXUV 0.00% 78 $ 2,098.20 Nov 12, 2026